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years) was used; after 8 years, patients were assumed to only be
at risk for death. Costs and outcomes were discounted at 3.5%
per annum. Sensitivity analyses were performed to identify inﬂu-
ential parameters in the model. RESULTS: Undiscounted mean
life expectancy for patients treated with FOLFOX4 was esti-
mated at 15.9 years. Assuming the addition of bevacizumab
reduces the risk of relapse by 23% in the ﬁrst 3 years after
surgery, as described in the protocol, and by 10% in the follow-
ing 5 years, mean survival was estimated to increase to 18.1 years
(10.8 to 12.1 years when discounted). The discounted ICER was
£19,939/life year gained. Sensitivity analysis showed that
assumptions relating to the magnitude of the relapse risk reduc-
tion and the duration of risk reduction were the most critical
determinants of the ICER. CONCLUSIONS: Addition of beva-
cizumab to FOLFOX4, the current standard regimen for patients
with stage III colon carcinoma, is expected to improve clinical
outcomes and to be a cost-effective treatment option from a UK
perspective.
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OBJECTIVES: The purpose of this study is to estimate the
cost-effectiveness (CE) of 1-year trastuzumab treatment versus
standard care (observation following standard adjuvant chemo-
therapy) in early stage breast cancer (eBC) patients in Portugal.
METHODS: A 5-state Markov model with annual transition
cycles was developed to estimate the long term health and eco-
nomic outcomes of eBC patients based on HERA clinical trial
results. The model included the following health states: disease
free survival, recurrence, metastasis, cardiac events and death.
The model assumes a hypothetical patient cohort similar to those
of HERA study. The evaluation assumes both the health care
payer and societal perspectives. Portuguese NHS resource use
and costs were estimated from a consensus experts panel and
published unit costs, respectively, including cancer therapy costs,
adverse cardiovascular events treatment costs, disease diagnosis
and management costs and indirect costs (time off of work).
Outcomes were discounted at 3% per annum. One-way sensitiv-
ity analysis was performed on the discount rate, quality of life
estimates and non-trastuzumab treatment costs. RESULTS:
Treatment with trastuzumab was estimated to increase dis-
counted life expectancy by 2.11 in years (14.95 vs 12,84) and
quality-adjusted life expectancy by 2.01 QALYs compared to
standard care. Direct and indirect costs were projected to be
€61.839 and €19,759 with trastuzumab and €40,559 and
€25.391 with standard of care. These results corresponded to
ICERs of €10,067 and €10,595 assuming direct costs only and of
€7789 and €7400 including indirect costs, per life year gained
(LYG) and per QALY gained, respectively. CONCLUSIONS: The
1-year trastuzumab use as adjuvant therapy in HER-2 positive
eBC patients improves survival and can be considered a cost
effective therapy with a high degree of certainty in the Portuguese
setting.
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OBJECTIVES: To obtain a Dutch cost-effectiveness estimate of
trastuzumab in early breast cancer, based on a previous UK
model-based cost-effectiveness analysis. Trastuzumab is a
humanized monoclonal antibody against the HER2-receptor
extracellular domain. METHODS: Following the model trans-
ferability assessment, required adjustments were made. In a
Markov cohort model, 1 year adjuvant trastuzumab therapy was
compared to observation. Model outcomes are life years,
quality-adjusted life years (QALYs), health care costs, and cost
of productivity loss. The cycle length is one year, the time
horizon is lifetime. UK prices were replaced by updated Dutch
unit prices. Clinical input data originated from the HERA-trial;
health utilities were obtained from literature. The impact of
parameter uncertainty was assessed using age subgroup analyses,
one-way sensitivity analyses and probabilistic sensitivity analy-
sis. Subsequently, we conducted expected value of perfect infor-
mation analyses. RESULTS: In The Netherlands, from a health
care perspective the ICER for trastuzumab for a 55 year old
patient was estimated at €19,463/QALY. From a societal per-
spective the ICER became €14,867. As expected, ICERs improve
with younger age. Sensitivity analyses showed that the ICER was
sensitive to the time horizon and the costs for the metastasic
health state. CONCLUSIONS: Overall the Dutch cost-
effectiveness estimate of trastuzumab for early stage breast
cancer can be well described and is well below the Dutch infor-
mal threshold of €80,000/QALY. For the base case analysis the
probability that the ICER is acceptable for thresholds above
€27.000/QALY is 1, indicating a probability of zero for a wrong
decision. Hence, for thresholds above €27,000 the expected
value of information is zero. This analysis provided an early
cost-effectiveness indication of trastuzumab in the adjuvant
setting in The Netherlands and has led to the provisional reim-
bursement. The transferability assessment is addressed in a sepa-
rate abstract.
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OBJECTIVES: Bevacizumab recently received a revised market-
ing authorisation for use in CRC that states “Bevacizumab in
combination with ﬂuoropyrimidine-based chemotherapy is indi-
cated for treatment of patients with metastatic carcinoma of the
colon or rectum”. This means that bevacizumab can be used in
combination with a wider choice of therapies than previously
allowed. This revised indication was based on the NO16966
phase III trial, which evaluated the efﬁcacy of bevacizumab
in combination with capecitabine + oxaliplatin (XELOX).
METHODS: A health state transition model was constructed to
estimate patient survival, stratiﬁed between progression-free sur-
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